Results 1 to 10 of about 38,526 (184)
Cancerous inhibitor of protein phosphatase 2A mediates bortezomib-induced autophagy in hepatocellular carcinoma independent of proteasome. [PDF]
PLoS ONE, 2013 Previously, we reported that cancerous inhibitor of protein phosphatase 2A (CIP2A) mediates the apoptotic effect of bortezomib in hepatocellular carcinoma (HCC).
Hui-Chuan Yu +6 more
doaj +1 more source
Molecules, 2023 Bortezomib is an inhibitor of proteasomes and an anti-cancer drug. Although bortezomib is considered a safe drug, as confirmed by cytotoxicity assays, recent reports highlighted the possibility of interaction between bortezomib and cellular components ...
Mihaela-Cristina Bunea +2 more
doaj +1 more source
Resensitising proteasome inhibitor-resistant myeloma with sphingosine kinase 2 inhibition
Neoplasia: An International Journal for Oncology Research, 2022 The introduction of the proteasome inhibitor bortezomib into treatment regimens for myeloma has led to substantial improvement in patient survival.
Melissa K. Bennett +12 more
doaj +1 more source
Alterations of the intracellular peptidome in response to the proteasome inhibitor bortezomib. [PDF]
PLoS ONE, 2013 Bortezomib is an antitumor drug that competitively inhibits proteasome beta-1 and beta-5 subunits. While the impact of bortezomib on protein stability is known, the effect of this drug on intracellular peptides has not been previously explored.
Julia S Gelman +7 more
doaj +1 more source
Asian Journal of Oncology, 2022 Objectives Bortezomib vial-sharing is commonly employed to maximize the treatment of patients with multiple myeloma (MM) in resource-limited setting. This strategy minimizes delays in treatment but reduces the dose of bortezomib received by the patient ...
Jeremiah R. Vallente +2 more
doaj +1 more source
Haematologica, 2015 Bortezomib-dexamethasone is widely used for relapsed myeloma in routine clinical practice, but comparative data versus single-agent bortezomib are lacking.
Meletios A. Dimopoulos +13 more
doaj +1 more source
Characterization of bortezomib-adapted I-45 mesothelioma cells
Molecular Cancer, 2010 Background Bortezomib, a proteasome-specific inhibitor, has emerged as a promising cancer therapeutic agent. However, development of resistance to bortezomib may pose a challenge to effective anticancer therapy.
Peddaboina Chander +5 more
doaj +1 more source
Journal of Hematology & Oncology, 2018 Background Although current chemotherapy using bortezomib (Velcade) against multiple myeloma in adults has achieved significant responses and even remission, a majority of patients will develop acquired resistance to bortezomib.
Zhihong Zheng +7 more
doaj +1 more source
Bortezomib Amplifies Effect on Intracellular Proteasomes by Changing Proteasome Structure
EBioMedicine, 2015 The proteasome inhibitor Bortezomib is used to treat multiple myeloma (MM). Bortezomib inhibits protein degradation by inactivating proteasomes' active-sites. MM cells are exquisitely sensitive to Bortezomib – exhibiting a low-nanomolar IC50 – suggesting
David S. Pitcher +5 more
doaj +1 more source
Gabapentin Inhibits Bortezomib-Induced Mechanical Allodynia Through Supraspinal Action in Mice
Journal of Pharmacological Sciences, 2014 Bortezomib, an inhibitor of proteasome holoenzyme, is used to treat relapsed and refractory multiple myeloma. Peripheral neuropathy is a treatment-limiting adverse effect of bortezomib and is very difficult to control.
Ryo Kitamura +5 more
doaj +1 more source